Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Serono Educational Efforts Turn To Brooke Shields

This article was originally published in The Pink Sheet Daily

Executive Summary

Educational campaign is part of effort to combat continued pricing pressures in the infertility segment from Organon.

You may also be interested in...



Serono Options Syntonix Technology To Produce Inhaled Infertility Therapy

Agreement builds on 2005 deal to develop inhaled interferon-beta therapy for muscular sclerosis.

Serono Options Syntonix Technology To Produce Inhaled Infertility Therapy

Agreement builds on 2005 deal to develop inhaled interferon-beta therapy for muscular sclerosis.

Serono Responds To Infertility Discounting With Gonal-f DTC Ads

Serono is aiming to offset heavy competitive discounting in the infertility treatment market through expansion of direct-to-consumer advertising and support programs for its Gonal-f therapy, the company said

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel